Trials / Terminated
TerminatedNCT02635061
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACY-241 | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2016-08-25
- Primary completion
- 2024-01-22
- Completion
- 2024-01-22
- First posted
- 2015-12-18
- Last updated
- 2024-05-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02635061. Inclusion in this directory is not an endorsement.